Phase 3 ASCENT-07 trial finds no progression-free-survival benefit for sacituzumab govitecan over chemotherapy in HR-positive breast cancer

Later-Stage HumanInvestigationalNot addressed

The randomized, open-label, phase 3 ASCENT-07 trial (ClinicalTrials.gov NCT05840211) compared sacituzumab govitecan (Trodelvy), an antibody-drug conjugate already FDA-approved for other breast-cancer indications, against standard-of-care chemotherapy as a first chemotherapy option in 690 patients with hormone-receptor-positive, HER2-negative advanced breast cancer previously treated with endocrine therapy. Presented at the San Antonio Breast Cancer Symposium on 2025-12-10, the trial did NOT meet its primary endpoint of progression-free survival by blinded independent central review: after a median follow-up of 15.4 months, median progression-free survival was 8.3 months in BOTH arms (hazard ratio 0.85), meaning sacituzumab govitecan did not outperform standard chemotherapy in this specific setting. This is a genuinely negative result for this particular combination and patient population — it does not call into question sacituzumab govitecan’s existing FDA approvals for its OTHER, already-approved indications, which this record makes no claim about.

What This Means

In the randomized, phase 3 ASCENT-07 trial, sacituzumab govitecan did NOT improve progression-free survival compared with standard-of-care chemotherapy as a first chemotherapy option for hormone-receptor-positive, HER2-negative advanced breast cancer -- median progression-free survival was 8.3 months in both arms (hazard ratio 0.85), a genuinely negative primary-endpoint result.

What This Doesn't Mean

This negative result is specific to THIS trial's particular setting (first chemotherapy after endocrine therapy, in this specific patient population) -- it does not call into question sacituzumab govitecan's existing FDA approvals for its OTHER, already-approved indications (including triple-negative breast cancer and previously treated HR-positive/HER2-negative breast cancer), which this record makes no claim about and which remain unaffected by this result.

Why It Matters

Reporting a well-powered, randomized phase 3 trial that did NOT show benefit is exactly the kind of honest, complete evidence picture this project's mission requires -- a real, negative result belongs on this site as much as a positive one, closing a second, independent example of the "What Did Not Work" topic area alongside Batch 5's fenbendazole myth-vs-evidence record.

Promise & Proof

Proof — strength of the evidence 4 / 5

Base score from evidence stage: Later-Stage Human.

Promise — potential significance if later evidence holds up 2 / 5

Baseline — a validly-evidenced story starts here; every further point below is an explicit, checkable reason.
The record includes substantive editorial reasoning about why this discovery matters.

These two ratings are automatically computed from this story's own structured evidence fields and are shown separately on purpose — they are never combined into one score. They describe this record, not a medical recommendation: they do not establish medical certainty, do not substitute for reading the cited sources, and are recalculated whenever the underlying evidence changes.

Population / Applicability

Studied in: Adults with hormone-receptor-positive, HER2-negative locally advanced, inoperable, or metastatic breast cancer previously treated with endocrine therapy and eligible for first-line chemotherapy, randomized 2:1 to sacituzumab govitecan or standard-of-care chemotherapy, in the randomized, open-label, phase 3 ASCENT-07 trial. (Adults)

A single trial in one specific clinical setting -- this record makes no broader claim about sacituzumab govitecan's value in other, already-approved settings. This record has not independently reviewed the trial's full safety/adverse-event data, which should be added before publication.

Full evidence details

Study design: Randomized controlled trial
Sample size: 690

Funding & Conflicts

Sponsor/developer: Gilead Sciences, Inc. -- not independently confirmed against a primary corporate-disclosure document.

Regulatory status by jurisdiction

Unspecified jurisdiction

Status: Investigational
Last verified: 2026-08-13

This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.

Guideline positions

Guideline

Position: Not addressed
Last verified: 2026-08-13

Primary evidence supporting this story

ASCENT-07 trial registry (opens in a new tab) (Clinical-trial registry) NCT05840211 Load-bearing source NCT05840211
ASCENT-07 trial registry. NCT05840211.

Why Should I Trust This?

1 source at Tier 1 — Government/regulatory authority (FDA, NCI, NIH, ClinicalTrials.gov, CDC, and equivalent)
Last reviewed: 2026-08-13

This panel summarizes real, checkable facts about this record's own sources and review status — it is not a trust score, and reading it is not a substitute for reading the cited sources yourself.

Discovery Timeline

Every recorded change to this record's content or publication status, in order.

2026-08-13 Status change — Status changed from "Legacy / Unverified" to "In editorial review".
2026-08-13 Status change — Status changed from "In editorial review" to "Verified".

Last reviewed 2026-08-13